Diabetes Autoimmune Profile
Use
Diabetes autoantibodies assessment is helpful in identifying and managing patients at risk for development of type 1 diabetes. Published positivity rates for diabetes autoantibodies in new-onset type 1 diabetes patients listed below are based on the combined analysis of GAD-65, ICA 512, insulin antibodies, and ZnT8 antibodies. The combined analysis has a 98% autoimmunity detection rate, with 1.8% diabetic individuals remaining as autoantibody-negative. fewer than 3% of type 2 diabetics have positive antibodies.1
Special Instructions
Ensure to transfer the specimen to a plastic transport tube before freezing to prevent delays in turnaround time. Submitted specimens should be frozen separately if requesting multiple tests to maintain integrity and prevent delays.
Limitations
Diabetes autoimmune panel is sensitive but not exhaustive. Approximately 1.8% of confirmed type 1 diabetics may test autoantibody-negative. Interpretation of results should consider the complete clinical context and any confirmatory testing may need additional time if required.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 8072-1
- 56540-8
- 31209-0
- 76651-9
- 8251-1
Result Turnaround Time
8-15 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.5 mL
Minimum Volume
1.0 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
Transfer specimen to a plastic transport tube before freezing. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Storage Instructions
Freeze. Stable at room temperature or refrigerated for one day. Stable frozen for seven days. Freeze/thaw cycles: stable x3.
Causes for Rejection
Gross hemolysis; lipemic specimen; EDTA plasma
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 day |
| Refrigerated | 1 day |
| Frozen | 7 days |